Montefiore Medical Center
montefiore.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
409
Active
79
Phase 3
29
Total enrollment
498,961
Pipeline matrix
Showing 40 of 58 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Metoclopramide | — | — | — | 10 | |||
| Acetaminophen | — | — | — | 7 | |||
| Dexamethasone | — | — | — | — | 7 | ||
| Naproxen | — | — | — | — | 6 | ||
| Ibuprofen 400 mg | — | — | — | — | — | 2 | |
| Lidocaine | — | — | — | — | — | 2 | |
| Metoclopramide 10mg | — | — | — | — | — | 2 | |
| Tranexamic acid | — | — | — | — | — | 2 | |
| Symptomatic treatment | — | — | — | — | — | 1 | |
| Amoxicillin-clavulanate | — | — | — | — | — | 1 | |
| Ciprofloxacin plus metronidazole | — | — | — | — | — | 1 | |
| Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL | — | — | — | — | — | 1 | |
| normal saline - | — | — | — | — | — | 1 | |
| normal saline - intravenous | — | — | — | — | — | 1 | |
| Fosaprepitant for | — | — | — | — | — | 1 | |
| DaxibotulinumtoxinA | — | — | — | — | — | 1 | |
| Acetaminophen 1000mg PO | — | — | — | — | — | 1 | |
| IV Acetaminophen 1000mg | — | — | — | — | — | 1 | |
| buprenorphine-naloxone | — | — | — | — | — | 1 | |
| Dexamethasone 16mg IM | — | — | — | — | — | 1 | |
| Prednisone 60mg PO | — | — | — | — | — | 1 | |
| Duloxetine | — | — | — | — | — | 1 | |
| Multimodal Pain Regimen | — | — | — | — | — | 1 | |
| Standard of Care Pain Regimen | — | — | — | — | — | 1 | |
| Dronabinol | — | — | — | — | 2 | ||
| Pilocarpine | — | — | — | — | — | 2 | |
| Prednisolone | — | — | — | — | — | 2 | |
| Ofloxacin | — | — | — | — | — | 2 | |
| Fosaprepitant 150 mg | — | — | — | — | — | 1 | |
| Ondansetron 4 mg | — | — | — | — | — | 1 | |
| Epidiolex 100 mg/mL Oral Solution | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | 3 | ||
| Decitabine | — | — | — | — | 2 | ||
| Mydfrin | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 | |
| Fianlimab | — | — | — | — | — | 1 | |
| Platinum Doublet Chemotherapy | — | — | — | — | — | 1 | |
| Desloratodine | — | — | — | — | — | 1 | |
| DFMO | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 |
18 more active programs hidden
Next readouts
- 2023-12-20
- 2025-07-01
- 2026-06
- 2026-06
- 2026-06
- 2026-10
- 2026-12
- 2027-01
- 2027-02
- 2027-03
Top conditions
- Asthma13
- Pain12
- Acute Pain11
- Migraine11
- Low Back Pain8
- HIV Infections6
- Breast Cancer6
- Hidradenitis Suppurativa5
Frequently asked questions about Montefiore Medical Center
- How many clinical trials does Montefiore Medical Center have on ClinicalTrials.gov?
- Montefiore Medical Center is listed as the lead sponsor on 409 clinical trials in ClinicalTrials.gov, 79 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Montefiore Medical Center's trials are in Phase 3?
- 29 of Montefiore Medical Center's trials are in Phase 3, spread across 58 active drug programs.
- What therapeutic areas does Montefiore Medical Center focus on?
- Montefiore Medical Center's most-studied conditions on ClinicalTrials.gov are Asthma, Pain, Acute Pain, Migraine, Low Back Pain.
- When are Montefiore Medical Center's next clinical trial readouts?
- Montefiore Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML”, expected around 2023-12-20.